Home Business First efficacy data on bivalent boosters shows they work against infection

First efficacy data on bivalent boosters shows they work against infection

by News Desk
0 comment
Expanding / White House Chief Medical Advisor Dr. Anthony Fauci speaks alongside COVID-19 Response Coordinator Dr. I’m here. Fauci spoke about his latest COVID-19 booster shot and urged individuals to vaccinate. (Photo by Win McNamee/Getty Images)

The updated bivalent COVID-19 booster vaccine provided enhanced protection against symptomatic disease compared to the original monovalent vaccine administered 2 months earlier.

it’s a takeaway from A study released Tuesday morning from the Centers for Disease Control and Preventionprovided the first clinical efficacy data for a bivalent shot since its nationwide rollout in September.

in adults, Relative The protective efficacy of the bivalent vaccine against symptomatic infection ranges from about 30% to up to 56% compared to that of the monovalent vaccine, and the relative efficacy is higher than the last time a person received the monovalent vaccine. It was estimated that the more time passed after inoculation, the larger it became.

The actual study of relative effectiveness is based on data from 360,000 people. The CDC researchers conducted the study between September 14th and he October 11th. At this time, the omicron subspecies BA.4/5 and its substrains predominated.

The study enrolled people already participating in a national program aimed at increasing COVID-19 testing in areas of high social vulnerability. The study investigated people with COVID-19-like symptoms who partnered with retail pharmacies for COVID-19 testing. Researchers collected test results, vaccinations, infection history, and other medical information. In this study, immunocompromised individuals were excluded.

Of the 360,626 tests performed, 121,687 (34%) were positive for COVID-19. Of those who tested positive only, 28,874 (24%) were unvaccinated, 87,013 (72%) received two to four doses of monovalent vaccine but not bivalent vaccine, 5,800 (24%) 5%) were those who received the bivalent vaccine. booster dose.

Relative effectiveness

For people aged 18–49 years, the relative vaccine efficacy (rVE) of a bivalent booster against symptomatic infections was 2–3 months prior to the most recent vaccine and 2 or more doses of monovalent vaccine. 30% compared to those who did. The rVE in this age group jumped to 56% when the last dose was administered more than 8 months before him and compared with those who received two monovalent doses.

In the same comparison of people aged 50-64, rVE ranged from 31% to 48%. For those 65 years and older, rVE ranged from 28% to 43%.

Table showing relative vaccine efficacy by age, number of vaccinations and time since last vaccination.
Expanding / Table showing relative vaccine efficacy by age, number of vaccinations and time since last vaccination.

“The results of this study show that bivalent boosters provided protection against symptomatic SARS-CoV-2 infection during circulation in BA.4/BA.5 and its substrains, and were observed to decrease after monovalent vaccination. The CDC authors concluded, “Every person should be kept up-to-date on the recommended COVID-19 vaccine for him if it has been more than two months since his last monovalent vaccination. It also includes a bivalent booster inoculation.”

This study has limitations, such as being based on self-reported data, not taking into account different exposure risks, combinations of immunizations and previous infections, and different behaviors such as mask wearing and social distancing. I have. Vaccine estimates may also change with future SARS-CoV-2 variants.

Overall, however, the bivalent vaccine “provides additional protection against infection compared to previous vaccination with two, three, or four monovalent vaccines alone.”

Fauci’s last message

At a White House press conference on Tuesday, top infectious disease expert Anthony Fauci stressed that more Americans should get fall booster injections before the year-end holidays and gatherings. Fauci’s White House appearance is likely to be his last in his current role as chief medical adviser to the president and leader of the NIH. Plan to retire by the end of the yearending a respected decades-long career in federal research.

On the podium today, he went through a list of reasons to get vaccinated. This includes protection against severe disease, robust safety data, and risk of future mutations. Next, we turned to new data from the CDC.

The clinical efficacy data are “very good,” Fauci said.

“We know [the booster] Safe. We know it works. So my message, and maybe the last message from this podium, is this. You are entitled to protect yourself, your family and your community. “

Ashish Jha, the White House’s COVID-19 response coordinator, agreed with Fauci’s call and said the administration today announced that Americans, especially seniors and nursing home residents, will be vaccinated against COVID-19 this fall. It also announced plans for a six-week campaign to increase

We are “doubling down” on our efforts, said Jha. “The bottom line is that more Americans need to be vaccinated.”

Current, Only 11.3% of eligible Americans Received a bivalent booster shot.

You may also like

Leave a Comment

Copyright ©️ All rights reserved. | Canadian Trends